Product Certification&
    Enterprise Certification

  • Mr.simon
    Tel: 86-021-58380978

  • Ms.Cecilia Wei
    Tel: 021-58380978

  • Mobile:13482386415
  • Tel:86-021-58380978
  • Fax:86-021-58380977
  • URL:http://www.systeambc.com
  • Province/state:shanghai
  • City:shanghai
  • Street:Building 87,Lane 669, Dong Jing Road Shanghai,P.R.China
  • MaxCard:
Home > Products >  Ibrutinib,PCI32765

Ibrutinib,PCI32765 CAS NO.936563-96-1

  • FOB Price: USD: 1.00-1.00 /Gram Get Latest Price
  • Min.Order: 100 Gram
  • Payment Terms: L/C
  • Available Specifications:

    ≥98.0%(100-1000)Gram≥98.0%(1000-5000)Gram

  • Product Details

Keywords

  • 936563-96-1
  • Ibrutinib,PCI32765
  • PCI-32765;1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one;PCI-32765 (Ibrutinib);(R)-1-(3-(4-aMino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyriMidin

Quick Details

  • ProName: Ibrutinib,PCI32765
  • CasNo: 936563-96-1
  • Molecular Formula: C25H24N6O2
  • Appearance: white powder
  • Application: Signal transduction pathway kinase inh...
  • DeliveryTime: 2 months
  • PackAge: 100g,500g,1kg,25kg/drum
  • Port: shang hai
  • ProductionCapacity: 1000 Gram/Week
  • Purity: ≥98.0%
  • Storage: Dry seal
  • Transportation: shipping
  • LimitNum: 100 Gram

Superiority

We are specialized in custom synthesis, chemical/pharmaceutical/ pesticides outsourcing and contract research.
 
 
 
We are committed to provide excellence in researching, manufacturing and drug discovery process.
 
 
 
Our research team of scientists consists of western-trained Ph.D.s with experience and capabilities in drug R&D methodologies and medicinal chemistry.

 

Details

PCI-32765(Ibrutinib) is a potent and highly selective Btk inhibitor with IC50 of 0.5 nM, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.
IC50 value: 0.3 nM
Target: Btk
in vitro: Ibrutinib shows the potent and irreversible inhibitory effect and selectivity for Btk enzymatic activity. In BCR pathway-activated DOHH2 cell line, Ibrutinib inhibits autophosphorylation of Btk, phosphorylation of Btk's physiological substrate PLCγ, and phosphorylation of further downstream kinase, ERK with IC50 of 11 nM, 29 nM and 13 nM, respectively [1]. Ibrutinib exhibits a significant dose-dependent and time-dependent induction of cytotoxicity in chronic lymphocytic leukemia (CLL) cells. In addition, Ibrutinib induces cell death depending on caspase pathway activation and antagonizes the ability of CLL cells to proliferate after TLR signaling [2]. A recent study shows that Ibrutinib inhibits BCR-activated primary B cell proliferation with IC50 of 8 nM and results in inhibition of TNFα, IL-1β and IL-6 production in primary monocytes with IC50 of 2.6 nM, 0.5 nM and 3.9 nM, respectively [3].
in vivo: In a collagen-induced arthritis model, Ibrutinib significantly reduces clinical arthritis scores reflecting paw swelling and joint inflammation by inhibiting B-cell activation. In a MRL-Fas(lpr) lupus model, Ibrutinib reduces renal disease and autoantibody production [1]. In an adoptive transfer TCL1 mouse model of CLL, Ibrutinib (25 mg/kg/day) causes a transient early lymphocytosis, and delays CLL disease progression [4].
 

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog